$RARE

CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Thursday - Broadcom (NASDAQ:AVGO), D

Analysts updated price targets for several companies. HC Wainwright cut Ultragenyx's (RARE) target to $25. Needham raised UiPath's (PATH) target to $22. BTIG increased Netskope's (NTSK) target to $18 and Snowflake's (SNOW) to $424. Needham also raised Magnite's (MGNI) target to $30. Cantor Fitzgerald boosted Broadcom's (AVGO) target to $600. Baird increased CrowdStrike's (CRWD) target to $235. Rothschild & Co raised Moderna's (MRNA) target to $81 but downgraded it. B of A cut Sonoco's (SON) targ

Original reporting
Published Sep 3, 2026, 12:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 6:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RARE
Bearish
medium confidence
Mentioned
$RARE · $PATH · $NTSK · $SNOW · $MGNI · $AVGO
Relevance
4/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$RAREBearishLow
01

Why it matters

Overall impact is modest as the revisions are incremental and lack fresh catalysts.

02

Market read

Analyst target revisions provide limited trading signals; most changes are modest and likely already reflected in prices.

03

What to watch

No new fundamental catalyst accompanies the revisions, reducing actionable insight.

Relevance 4/10Novelty 2/10Timing: today

Background

The article aggregates recent analyst price target updates for a set of U.S.-listed companies.

Company-level read

Ticker impact

$RAREBearishMedium confidence
Context

HC Wainwright cut Ultragenyx price target to $25, indicating lowered expectations.

Expected impact

Modest decline if market reacts.

Evidence & confidence

Analyst target cut suggests weaker outlook; no new catalyst beyond the downgrade.

$PATHBullishMedium confidence
Context

Needham raised UiPath price target to $22, signaling improved outlook.

Expected impact

Small rally if investors follow the upgrade.

Evidence & confidence

Target increase reflects bullish view but lacks a concrete catalyst.

$NTSKNeutralLow confidence
Context

BTIG boosted Netskope price target to $18, a modest increase.

Expected impact

Little price movement expected.

Evidence & confidence

Small target change; market likely already priced in.

$SNOWBullishMedium confidence
Context

BTIG raised Snowflake price target to $424 from $340.

Expected impact

Moderate rally if investors act on the higher target.

Evidence & confidence

Significant target lift suggests strong confidence, but no new fundamental data.

$MGNIBullishLow confidence
Context

Needham increased Magnite price target to $30 from $25.

Expected impact

Small upside possible.

Evidence & confidence

Target raise modest; limited market impact.

$AVGOBullishMedium confidence
Context

Cantor Fitzgerald boosted Broadcom price target to $600 from $525.

Expected impact

Potential price gain if market follows.

Evidence & confidence

Target increase reflects optimism but lacks a fresh catalyst.

$CRWDBullishLow confidence
Context

Baird raised CrowdStrike price target to $235 from $230.

Expected impact

Minor upside possible.

Evidence & confidence

Small target bump; no new material news.

$MRNANeutralLow confidence
Context

Rothschild raised Moderna price target to $81 from $40 but downgraded to Sell.

Expected impact

Unclear direction; market may stay flat.

Evidence & confidence

Target increase offset by downgrade; ambiguous impact.

Market effects

Analyst target revisions across tech and biotech may slightly shift sector sentiment.

U.S. equities may see modest volatility in the affected stocks.

Limited; primarily U.S. market focus.

Counterpoint

Target changes are minor and may already be priced in; traders could ignore.

Key entities

  • HC Wainwright

    Provided price target cut for Ultragenyx.

  • Needham

    Raised targets for UiPath, Magnite.

  • BTIG

    Adjusted targets for Netskope, Snowflake.

  • Cantor Fitzgerald

    Boosted Broadcom target.

  • Baird

    Raised CrowdStrike target.

Related articles

$RAREHighAI 9/10

Ultragenyx agrees to sell voucher for US$210M

Ultragenyx Pharmaceutical (NASDAQ: RARE) agreed to sell a rare pediatric disease priority review voucher for $210M, nearly half its cash reserves. The deal, subject to regulatory approval, follows the FDA's August approval of its Genglycos gene therapy. Shares rose 2.97% on the news. Ultragenyx plans to use proceeds to advance rare disease therapies and support profitability. The price is within the range of recent voucher transactions, such as Rocket Pharmaceuticals' $180M deal.

$DKNGLow

DraftKings' Elasticity Score Explainer

DraftKings faces a proposed class action lawsuit alleging it used AI to target customers likely to lose more money with promotions. The plaintiff claims the company's 'elasticity score' model violated privacy notices and Massachusetts regulations. DraftKings denies the allegations and plans to defend the case vigorously. The Massachusetts Gaming Commission is reviewing AI use by sportsbooks but has not found wrongdoing by DraftKings.